MetaVia reports positive Phase 1 MAD data for DA-1726 obesity drug: 6.3% max weight loss, strong glucose control

MetaVia Inc.

Mean weight loss 4.3% (max 6.3%) at 32 mg dose on Day 26 (p=0.0005).
Fasted glucose lowered by mean 5.3 mg/dL (max 18 mg/dL); waist circumference reduced mean 1.6 in (max 3.9 in).
No SAEs or discontinuations; mild GI AEs transient, 83% of 32 mg cohort reported early satiety.
Adding higher-dose cohorts to determine MTD; planning Phase 1 Part 3 in Wegovy early drop-out patients.
Company cites balanced GLP-1/glucagon activation as potential best-in-class profile for safety and efficacy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.